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Background
Glioblastoma multiforme (GBM) is the most common
primary malignant human brain tumor and one of the
most lethal of all cancer types. Despite the introduction
of numerous non-surgical therapies for GBM, clinically
relevant responses to treatment are rarely durable. Small
populations of stem cells residing within GBM tumors
have the ability to differentiate into diverse cell types in
vitro and in vivo, and form new heterogeneous tumors
in immune compromised mice. These cells have been
found to express high amounts of aldehyde dehydrogenase
(ALDH), can resist radiation therapy and chemotherapy,
and represent an important target in the advancement of
glioblastoma treatment.
Methods
We and others have identified natural killer (NK) cells as
having an inherent ability to kill human GBM stem cells
(GSCs), through the recognition of specific activating
proteins on the GSC surface which facilitate NK cell,
activation, recognition, and killing. Here we found that
primary human GBMs contain a small population of cells
(4-14%) expressing high amounts of the stem cell asso-
ciated protein ALDH which can be selectively killed by
activated human NK cells.
Results
Bortezomib, a small molecule proteasome inhibitor, has
previously been found to sensitize human and mouse
tumor cells to TRAIL and/or NK cell-mediated killing
through the expression of apoptosis-inducing death recep-
tors such as DR5. Additionally bortezomib has proved to
have some anecdotal efficacy for adults with recurrent
gliomas in early clinical trials. In this study we found that
bortezomib significantly improves activated human NK
cell killing of ALDHbright human GSCs. Additionally we
found that in vitro bortezomib treatment significantly
enhances human GSC expression of Fas and DR5, while
having a much smaller effect on ALDHdim cells. Lastly,
utilizing an orthotopic xenograft model of human GBM in
the brains of NSG mice, we found that the administration
of bortezomib prior to intracranial human activated NK
cell infusions led to significant increases in tumor growth
delay compared to either bortezomib or NK cells alone.
Conclusions
These data provide preclinical rational for the combined
use of bortezomib and adoptive NK cell therapy for the
treatment of human GBM, with the potential to kill
ALDHbright GSCs.
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